2 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-PositiveHER2-positive Breast CancerRecruitingPhase 2 / Phase 32026-10-06NCT07413939
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancerinvasive breast carcinomaActive, not recruitingPhase 32024-03-06NCT03595592